SYNGENE INTERNATIONAL LIMITED Syngene International Limited Share Price Bombay S.E.
Equities
SYNGENE
INE398R01022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 698.2 INR | -0.10% |
|
-2.11% | -0.41% |
| Sales 2024 | 34.89B 418M 33.5B | Sales 2025 * | 39.35B 472M 37.78B | Capitalization | 278B 3.33B 267B |
|---|---|---|---|---|---|
| Net income 2024 | 5.1B 61.17M 4.9B | Net income 2025 * | 5.67B 68.05M 5.45B | EV / Sales 2024 | 7.73 x |
| Net cash position 2024 | 9.35B 112M 8.98B | Net cash position 2025 * | 9.1B 109M 8.74B | EV / Sales 2025 * | 6.83 x |
| P/E ratio 2024 |
55.4
x | P/E ratio 2025 * |
50.9
x | Employees | 6,847 |
| Yield 2024 |
0.18% | Yield 2025 * |
0.18% | Free-Float | 44.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on Syngene International Limited
More recommendations
More press releases
| 1 day | -0.10% | ||
| 1 week | -2.11% | ||
| Current month | -0.49% | ||
| 1 month | -0.92% | ||
| 3 months | +1.78% | ||
| 6 months | +2.23% | ||
| Current year | -0.41% |
1 week
668.85
732.20
1 month
668.85767.75
Current year
660.35775.45
1 year
652.30860.20
3 years
508.10860.20
5 years
201.65860.20
10 years
147.50860.20
| Managers | Title | Age | Since |
|---|---|---|---|
Jonathan Hunt
CEO | Chief Executive Officer | 55 | 28/02/15 |
Sibaji Biswas
DFI | Director of Finance/CFO | - | 17/12/19 |
| Chairman | 71 | 17/11/94 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 17/11/94 | |
| Director/Board Member | 67 | 30/07/17 | |
Jonathan Hunt
CEO | Chief Executive Officer | 55 | 28/02/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 698.2 | -0.10% | 29,097 |
| 25/04/24 | 699 | +0.68% | 109,155 |
| 24/04/24 | 694.2 | -1.00% | 23,317 |
| 23/04/24 | 701.2 | -0.52% | 12,092 |
| 22/04/24 | 704.8 | -1.18% | 9,397 |
Delayed Quote Bombay S.E., April 26, 2024 at 11:00 am
More quotes
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
Calendar
23/07/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
698.6
INR
Average target price
725.1
INR
Spread / Average Target
+3.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SYNGENE Stock
- SYNGENE Stock
